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Abstract
Background: Lung cancer is one of the most malignant tumors, representing a significant threat to human
health. Lung cancer patients often exhibit tumor cell invasion and metastasis before diagnosis which often
render current treatments ineffective. Here, we investigated the effect of staurosporine, a potent protein
kinase C (PKC) inhibitor on the mobility and invasiveness of human lung adenocarcinoma A549 cells.
Methods: All experiments were conducted using human lung adenocarcinoma A549 cells that were either
untreated or treated with 1 nmol/L, 10 nmol/L, or 100 nmol/L staurosporine. Electron microscopy
analyses were performed to study ultrastructural differences between untreated A549 cells and A549 cells
treated with staurosporine. The effect of staurosporine on the mobility and invasiveness of A549 was
tested using Transwell chambers. Western blot analyses were performed to study the effect of
staurosporine on the levels of PKC-α, integrin β1, E-cadherin, and LnR. Changes in MMP-9 and uPA levels
were identified by fluorescence microscopy.
Results: We demonstrated that treatment of A549 cells with staurosporine caused alterations in the cell
shape and morphology. Untreated cells were primarily short spindle- and triangle-shaped in contrast to
staurosporine treated cells which were retracted and round-shaped. The latter showed signs of apoptosis,
including vacuole fragmentation, chromatin degeneration, and a decrease in the number of microvilli at the
surface of the cells. The A549 cell adhesion, mobility, and invasiveness significantly decreased with higher
staurosporine concentrations. E-cadherin, integrin β1, and LnR levels changed by a factor of 1.5, 0.74, and
0.73, respectively compared to untreated cells. In addition, the levels of MMP-9 and uPA decreased in cells
treated with staurosporine.
Conclusion: In summary, this study demonstrates that staurosporine inhibits cell adhesion, mobility, and
invasion of A549 cells. The staurosporine-mediated inhibition of PKC-α, induction of E-Cad expression,
and decreased integrin β1, LnR, MMP-9, and uPA levels could all possibly contribute to this biological
process. These results represent a significant step forward in the ongoing effort to understand the
development of lung carcinoma and to design novel strategies to inhibit metastasis of the tumor by
targeting the cell-adhesion, mobility and invasion of tumor cells.
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Background
Lung cancer is one of the most malignant tumors and rep-
resents a significant threat to human health. The strong
invasive and metastatic characteristics of lung tumor cells
are responsible for its relatively high malignancy. Indeed,
patients with lung cancer often exhibit tumor cell inva-
sion and metastasis before diagnosis which renders cur-
rent treatments, including surgery, radiotherapy, and
chemotherapy ineffective. Typically, 85% of lung cancer
patients die within a period of 5 years after diagnosis.
Therefore, studying the molecular basis of lung cancer cell
invasion and metastasis is crucial in order to design new
therapeutic agents that prevent or slow lung cancer cell
invasion and metastasis.
Tumor cell invasion and metastasis are inter-related proc-
esses associated with adhesion of tumor cells, hydrolysis
of the extracellular matrix, cell mobility, and the regula-
tion and expression of metastasis related genes. Protein
kinases are involved in all of the above mentioned proc-
esses. Protein kinase C (PKC), an important member of
the protein kinase family, is a calcium-activated and phos-
pholipid-dependent serine/threonine protein kinase. PKC
phosphorylates a number of substrates to mediate a series
of physiological responses, including cell growth, prolifer-
ation, differentiation, apoptosis, and mobility [1-4]. Fur-
thermore, PKC is also important for the maintenance of
normal physiological functions of cells [5]. It has been
demonstrated that the PKC level, which is closely related
to the invasiveness and metastasis of tumor cells, is
enhanced in some tumors [6]. It was recently shown that
the level of PKC-α is significantly higher in lung cancer tis-
sue when compared to healthy lung tissue, and its traffick-
ing to the cell membrane and the nuclei is also increased
significantly [7,8]. Moreover, examination of clinical sam-
ples showed that the levels of PKC-α protein correlated
with lung cancer TNM staging. Higher PKC-α levels were
seen in more advanced stages with higher metastatic and
invasive capabilities. It has been suggested that the over-
expression of PKC-α and its cytomembrane transporta-
tion play a role in regulating the progress and metastasis
of lung cancer cells [7,8]
Staurosporine is a potent inhibitor of PKC and many
other kinases, including the tyrosine protein kinase. It
blocks the transfer of the phosphate ester from DNA to the
activated tyrosine sites and directly inhibits the activity of
topoisomerase II. It has been reported [9,10] that stau-
rosporine can induce apoptosis of a variety of cells,
including cardiac cells, oral squamous cell carcinoma
cells, and fibroblasts. Therefore, staurosporine is widely
used to study apoptosis and has become one of the most
promising anti-cancer drugs. Although staurosporine has
been well studied in the context of apoptosis in cancer
cells, not much information is available on the role of
staurosporine on cell adhesion, mobility and invasion in
lung cancer in the context of tumor metastasis.
Based on the above information, we hypothesized that
staurosporine-mediated inhibition of PKC could affect
the invasive and metastatic capabilities of lung tumor
cells, exerting its anti-tumor function through mecha-
nisms other than the induction of apoptosis. In this study,
we treated human lung adenocarcinoma A549 cells with
staurosporine and investigated the relationship between
staurosporine treatment and tumor cell adhesion, mobil-
ity, and invasiveness. We also studied the effect of stau-
rosporine on the levels of adhesion molecules, including
integrin β1, E-cadherin, LnR, and on the levels of proteo-
lytic enzymes MMP-9 and uPA. The feasibility of using
staurosporine as a compound that blocks invasion and
metastasis of lung tumor cells was explored.
Methods
Cell line and experimental grouping
Human lung adenocarcinoma cell line A549 was obtained
from the American Typical Culture Center (ATCC), pas-
saged and preserved at the Chinese Culture Center,
Wuhan University (Wuhan, China). The cells were cul-
tured in RPMI 1640 medium (free of phenol red) contain-
ing 10% FCS and maintained at 37°C in 5% CO2.
Staurosporine (Sigma, St. Louis, MO) was dissolved in
dimethyl sulfoxide (DMSO) to a final concentration of 1
nmol/L, 10 nmol/L, and 100 nmol/L [6]. For the control
experiments, cells were incubated in RPMI 1640 medium
containing 0.1 ‰ DMSO and 10% FCS (without stau-
rosporine).
Adhesion experiment
96-well plates were coated with Matrigel (Department of
Cell Biology, School of Medicine, Peking University, Bei-
jing, China) and air dried in a laminar hood overnight.
The wells were blocked with 2% bovine serum albumin
(BSA; 50 μL/well) and incubated at 37°C for 2 h. A549
cells were inoculated into the 96-well plate at a concentra-
tion of 1 × 103 cells/well. The medium was discarded after
2 h, and wells were washed with 200 μL phosphate-buff-
ered saline (PBS) to remove unattached cells. Subse-
quently, 12 μL MTT (Sigma; 5.0 mg/mL) was added into
each well and the samples were incubated at 37°C for 4 h.
Isopropanol (100 μL) was added into each well and the
samples were mixed well. The purplish-blue crystals were
dissolved at room temperature. The absorbance (A) at λ =
540 nm was read on the spectra Max Plus 384 Molecular
Devices (Sunnyvale, CA) and the data were analyzed. Each
group consisted of four duplicates and the cell adhesion
inhibition rate was calculated using the following equa-
tion:BMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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Inhibition rate = (A of control group - A of drug adminis-
tration group)/A of control group × 100%.
Cell mobility experiment
Transwell chambers (Costar, Bethesda, MD) were used in
the cell mobility experiments. Cells were inoculated into
the upper compartment of the Transwell chambers at a
concentration of 1 × 105 cells/mL and 100 μL/well. The
medium for the experimental and control group was
added into the lower compartment of the Transwell
chambers (500 μL/well). The cells were cultured at 37°C
for 10 h. Cells that did not penetrate the polycarbonate
membrane at the bottom of the chamber were wiped off
with cotton stickers. The membrane was removed and
fixed with methanol and stained with Hematoxylin &
Eosin. Five vision fields were randomly selected under a
BX50 microscope (Olympus, Tokyo, Japan) and the
number of cells that penetrated the membrane was
counted. Each group consisted of four duplicates. The
mobility inhibition rate was calculated using the follow-
ing equation:
Mobility inhibition rate = (number of cells in control
group that penetrated the membrane - number of cells in
the staurosporine group that penetrated the membrane)/
number of cells in control group that penetrated the
membrane × 100%.
Cell invasion experiment
Transwell chambers were used to determine the cell inva-
siveness. The membrane at the bottom of the Transwell
chamber was evenly coated with 50 μL Matrigel and air
dried in a laminar hood overnight. The samples were
blocked with 2% BSA, 50 μL/well and incubated at 37°C
for 2 h and were then rinsed with PBS buffer. Cells were
inoculated into the upper compartment of the Transwell
chambers at a concentration of 2 × 105 cells/mL and 100
μL/well. The medium for the experimental and control
group was added into the lower compartment of the Tran-
swell chamber (500 μL/wel)l. The cells were cultured at
37°C for 48 h. Cells that did not penetrate the polycar-
bonate membrane at the bottom of the chamber were
wiped off with cotton stickers. The membrane was
removed and fixed with methanol and stained with HE.
Five vision fields were selected randomly under the BX50
microscope (Olympus), and the number of cells that pen-
etrated the membrane was counted. Each group consisted
of duplicates. The invasion inhibition rate was calculated
using the following equation:
Invasion inhibition rate = (number of cells in control
group that penetrated the membrane - number of cells in
staurosporine group that penetrated the membrane)/
number of cells in control group that penetrated the
membrane × 100%.
MTT assay
A549 cells were inoculated in 96 well plates at 1 × 105
cells/well in phenol-red free RPMI 1640 medium. After
drug treatment, 12 μL MTT (5.0 mg/mL) was added into
each well and the cells were incubated at°C for 4 h. After
incubation, 100 μL isopropanol was added into each well
and the samples were mixed well. The purplish-blue crys-
tals were dissolved at room temperature. The absorbance
(A) at λ = 540 nm was read on the spectra Max Plus 384
FACS apoptosis assay
Cells were collected and digested with 0.25% trypsin and
0.02% EDTA (1:1) at 37°C for 3–4 min. Cells were pipet-
ted gently and then collected by centrifugation at 1000
rpm for 5 min. They were then washed twice with cold
PBS (0.01 M pH 7.4) and resuspended in the residual PBS.
After adding 1 mL prechilled (-20°C) 80% ethanol, the
cells were stored at -20°C over night. After washing twice
with PBS, 60–80 μL RNAase (1 mg/mL) was added and
cells incubated at 37°C for 30 min. After chilling on ice
for 2 min, PI solution (100 mg/L PI, 0.1% TritonX-100)
was added and the sample was incubated in the dark for
30 min. The cell cycle distribution and apoptosis were
analyzed by flow cytometry (FACSCalibur, Becton Dickin-
son, Franklin Lakes, NJ USA). Data acquired by CEL-
LQuest was analyzed using the software ModFit LT that
came with the machine.
Transmission electron microscope
A549 cells cultured for 24 h, were collected from the cul-
ture flask wall with a cell shovel and prepared as a cell sus-
pension of 1 × 106 cells/ml. The samples were centrifuged
at 1000 rpm/min for 10 min, and the supernatant was dis-
carded. Samples were rinsed with 0.01 M PBS twice. Phos-
phate buffer containing 2.5% glutaraldehyde was added
and the samples were fixed for 30 min. The samples were
then fixed with 1% osmium tetroxide for 30 min, dehy-
drated using a concentration series of ethanol and embed-
ded using epoxy resin Epon812. Thin sections were made
using a LKB-5 type ultra-thin slicing instrument (LKB
Nova, Bromma, Sweden). The slices were stained with
uranyl acetate/lead citrate and observed under the H-600
transmission electron microscope (Hitachi, Ltd., Tokyo,
Japan).
Western blot analyses
Cytoplasmic and cell membrane proteins were prepared
as described [9]. 5 mL protein extracting liquid A (20
mmol/L Tris HCl (pH 7.5), 0.125 mol/L sucrose, 2 mmol/
L EDTA, 015 mmol/L EGTA, 10 mg/L leupeptin, and 50
mmol/L  β-mercaptoethanol) containing 1 mmol/L
freshly added protease inhibitor mix was added to the cell
samples. The samples were dissolved on an ice bath for 10
min and centrifuged at 4°C, 100,000 × g for 1 h. The col-
lected supernatant contained cytoplasmic proteins. 5 mLBMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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protein extracting liquid B (enzyme extracting liquid A
plus 5% Triton X-100) was added, the samples were
stirred at 4°C for 1 h and then centrifuged at 100,000 × g
for 1 h at 4°C. The supernatant containing the cell mem-
brane proteins was stored at -80°C until use. Protein
quantification was performed using the BCA kit (Bio-rad,
Hercules, CA) according to the instructions of the manu-
facturer.
Total protein (50 μg/lane) was electrophoresed using a
PAC300 electrophoresis instrument (Bio-Rad) according
to the instructions of the manufacturer. Proteins were
then transferred to a cellulose nitrate membrane using an
electrophoretic transfer instrument (Bio-Rad). Western
blot analyses were performed and the bands visualized
using an ECL kit (GE Healthcare, WA). All the required
antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Films were developed using an X-
XQF-2000 gel imaging system (Jianan Photoelectric Ltd.,
Nanjing, China). Quantitation was done by estimating
the optical density of the bands. The β-actin band was
used as a normalizing control.
MMP-9 and uPA immunofluorescent staining
Cells were inoculated into culture wells with a strip-
shaped cover slip, incubated for 48 h and rinsed with PBS
twice. The cells were fixed with cold acetone for 10 min
and stored at -20°C until use. Immunofluorescent stain-
ing was performed as follows. The cell climbing slices
were soaked in 1% Triton-TBS buffer for 30 min and
rinsed with PBS. Samples were blocked with non-immune
animal serum at 37°C for 15–20 min and incubated in
the diluted first antibody at 4°C overnight. The samples
were rinsed with PBS and then incubated in the dark with
second antibody labeled with the corresponding fluores-
cein moiety at 37°C for 2 h. Samples were rinsed with PBS
and observed under a Leica DM LB2 fluorescence micro-
scope (Leica, Wetzlar, Germany). For the negative control,
the first antibody was replaced by PBS and the remaining
procedures and reagents were unchanged. The appearance
of red fluorescent areas in the cytoplasm was associated
with the presence of MMP-9; the appearance of green flu-
orescent areas in the cytoplasm was associated with the
presence of uPA. Intracellular protein levels were meas-
ured using the automatic image analysis instrument of the
microscope system. Using the 200× magnified visual field,
100 cells were randomly selected from the upper, lower,
left, right, and central zones of the slides in the same
experiment. The average optical density (OD) value of the
fluorescent particles was measured and the measurement
was repeated four times. The data were shown in mean ±
standard deviation (  ± s).
Statistical analysis
The experimental data are shown in mean ± standard
deviation (  ± s). The one-way ANOVA was used for the
comparisons among the means. All the analyses were car-
ried out using the SPSS13.0 software (SPSS Inc, Chicago,
IL). The significance level was set at P < 0.05.
Results
Effects of staurosporine on the cell morphology
Electron microscopy analyses demonstrated that
untreated A549 cells were short spindle-shaped and trian-
gle-shaped. They exhibited characteristics resembling
those of epithelial cells (Figure 1A). Upon treatment with
1 nmol/L staurosporine for 24 h, morphological changes
were observed. A549 cells became long spindle-shaped
and narrow protrusions appeared. In addition, some
small cavities were observed in the cytoplasm of some
cells (Figure 1B). Twenty-four hours after treatment with
10 nmol/L staurosporine, some A549 cells retracted and
gradually became round-shaped (Figure 1C). When the
staurosporine dose increased to 100 nmol/L, the cells
gradually became round-shaped and the number of shed-
ding cells increased after 24 hours of treatment (Figure
1D).
Effect of staurosporine on A549 cell adhesion
We showed that different concentrations of staurosporine
could inhibit the adhesion of the A549 cells to Matrigel,
and the inhibition was proportional to the concentration
of staurosporine (Table 1). The inhibition rate at a stau-
rosporine concentration of 10 nmol/L and 100 nmol/L
reached 50% and 74%, respectively. Compared to that of
the untreated cells, this difference was significant (P <
0.01) (Table 1).
Effect of staurosporine A549 cell mobility and invasion
We also demonstrated that staurosporine could inhibit
the mobility and invasion capability of the A549 cells in
vitro. This effect was dose-dependent (Table 2). There was
a significant difference in the mobility and invasion of
untreated cells versus cells treated with a staurosporine
concentration of 10 nmol/L and 100 nmol/L (P < 0.05)
(Table 2).
Effect of staurosporine on cell proliferation and apoptosis
The MTT assay showed that the cell proliferation of A549
cell was significantly inhibited by staurosporine in a dose
dependent manner. (Figure 2). FACS assay showed that 6
hours treatment with 100 nM staurosporine caused a sig-
nificant increase in G2/M arrest and apoptosis. The G2/M
arrest reached its peak at 12 hours treatment and apopto-
sis reached its peak at 24 hours treatment (Table 3).
x
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Ultrastructural changes in A549 cells treated with 
staurosporine
Untreated A549 cells exhibited homogenized chromatin,
dense intracytoplasmic rough endoplasmic reticulum,
and a large number of ribosomes (Figure 3A). Many
microvilli were observed on the cell surface. However, 24
h after treatment with 100 nmol/L staurosporine, the
number of microvilli on the cell surface decreased, chro-
matin coagulation was observed in the nuclei resulting in
a plate-like appearance, the nuclear apertures expanded
and the cytoplasmic mitochondria were swollen (Figure
3B). The endoplasmic reticulum expanded, and cytoplas-
mic vacuoles appeared. Vesicles formed that were sur-
rounded by a cell membrane, and some of them
contained nuclear debris, which is a typical morphologi-
cal feature of apoptosis (Figure 3B).
Effect of staurosporine on the PKC-α level and membrane 
translocation of the A549 cells
The results of the Western blot analyses showed that
although PKC-α was mainly present in the cytoplasm, it
was also seen on cell membranes of untreated A549 cells
Effect of staurosporine on the A549 cell morphology Figure 1
Effect of staurosporine on the A549 cell morphology. A: A549 cells in the control group. Cells were short, spindle-
shaped and triangle-shaped and resembled epithelial cells (200 ×). B: A549 cells treated with 1 nmol/L staurosporine for 24 h. 
Some of the cells were long spindle-shaped and exhibit slender protrusions (arrows). Small cavities were visible in the cyto-
plasm of some cells (arrow heads) (200 ×). C: A549 cells treated with 10 nmol/L staurosporine for 24 h. Some A549 cells 
retracted and became gradually round-shaped (arrows) (200 ×). D: A549 cells treated with 100 nmol/L staurosporine for 24 h. 
Some A549 cells retracted, became gradually round-shaped, and shed off (arrows) (200 ×).
Table 1: Effect of staurosporine on adhesion of A549 cells (  ± s, n = 4)
Group A-value Inhibition rate (%) Compared with the control group, P-value
Control group 0.381 ± 0.023 Not applicable Not applicable
1 nmol/L staurosporine 0.317 ± 0.005 17 0.132
10 nmol/L staurosporine 0.189 ± 0.014 50 <0.001
100 nmol/L staurosporine 0.010 ± 0.013 74 0.000
xBMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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(Figure 4). In A549 cells treated with 100 nM stau-
rosporine for 24 h, the PKC-α level in the cell membrane
decreased by 38% (P < 0.01) (Figure 4). No significant dif-
ferences in the cytoplasmic PKC-α content were observed,
suggesting that staurosporine inhibited the activation of
PKC-α (Figure 4).
Effect of staurosporine on the levels of integrin β1, E-
cadherin, and LnR
The Western blot analyses showed that the level of E-cad-
herin increased and the level of integrin β1 decreased in
A549 cells treated with 100 nM staurosporine for 24 h
(Figure 5). The protein contents of E-cadherin, integrin
β1, and LnR changed by a factor 1.5, 0.74, and 0.73,
respectively, compared to that in untreated cells (P < 0.01)
(Figure 5).
Localization of MMP-9 and uPA by immunofluorescence 
microscopy
The intracytoplasmic level of MMP-9 in untreated A549
cells was relatively high (Figure 6A, Table 4). Image anal-
ysis showed a 57.39% decrease (P < 0.01) in the intracy-
toplasmic fluorescence reflecting MMP-9 levels twenty-
four hours after treatment with 100 nM staurosporine
(Figure 6B, Table 4). The intracytoplasmic level of uPA in
untreated A549 cells was relatively high (Figure 6C, Table
4). However, image analysis showed a 48.37% decrease (P
< 0.01) in the intracytoplasmic fluorescence reflecting
uPA levels twenty-four hours after treatment with 100 nM
staurosporine, (Figure 6D, Table 4).
Discussion
PKC inhibitor staurosporine has become one of the most
promising anti-cancer drugs because of its apoptosis pro-
moting effects in tumor cells. This study analyzed the
effects of staurosporine on the invasive and metastatic
capabilities of lung cancer tumor cells. The results of the
cell adhesion experiment in this study showed that stau-
rosporine (100 nmol/L) inhibited the adhesion of A549
cells to Matrigel by 74%. The results of the mobility and
invasion experiments showed that staurosporine inhib-
ited the mobility and the invasion of A549 cells by 56%
and 54%, respectively. It can be argued that the extent of
apoptosis occurring at the highest dose of staurosporine
(100 nmol) could have resulted in the lower rates of inva-
sion seen at this dose. However, the lower dose of stau-
rosporine (1 nmol) where there was no significant
apoptosis seen, also resulted in a decrease in cell mobility
and invasion by 15% and 16% respectively (Figure 2,
Table 2).
Tumor invasion and metastasis are hallmarks of malig-
nant tumors and constitute a major cause of ineffective
treatment resulting in death of cancer patients. Inhibition
of the invasion and metastasis of tumor cells could be a
new pathway in the treatment of patients with cancer.
Tumor invasion and metastasis is a complex, continuous,
multi-step process where metastatic lesions develop in a
defined pathway which includes the diffusion of the
tumor cells from the primary site, the infiltration of extra-
cellular matrix (ECM), penetration through the vessel
walls, intravascular aggregation, and adhesion to the vas-
Table 2: Effect of staurosporine on the mobility and invasiveness of A549 cells (  ± s, n = 4)
Group Mobility Invasiveness
Cells that penetrate 
membrane
Mobility inhibition rate P-
value
Cells that penetrate 
membrane
Invasion inhibition rate P-
value
Control group 149.00 ± 7.12 74.50 ± 4.20
1 nmol/L staurosporine 126.50 ± 5.57 15% 0.002 62.75 ± 3.86 16% 0.015
10 nmol/L 
staurosporine
111.75 ± 7.80 25% <0.001 46.75 ± 5.91 37% <0.001
100 nmol/L 
staurosporine
65.50 ± 5.32 56% <0.001 34.00 ± 2.94 54% <0.001
x
Table 3: Effect of staurosporine on cell cycle distribution and apoptosis of A549 cells.n = 3. Mean ± SD. a P > 0.05, cP < 0.01 vs control.
Groups/h Cell cycle/% Apoptosis/%
G0/G1 SG 2/M
Control 58.9 ± 1.0 31.2 ± 2.1 9.9 ± 1.2 2.9 ± 0.3
Staurosporine 6 h 58.4 ± 1.9a 15.0 ± 0.4c 26.6 ± 1.8c 7.3 ± 0.4c
Staurosporine 12 h 56.0 ± 0.7a 9.9 ± 0.4c 34.0 ± 1.0c 10.6 ± 1.5c
Staurosporine 24 h 59.5 ± 1.0a 20.7 ± 0.1c 19.8 ± 0.9c 27.4 ± 0.7cBMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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Effect of staurosporine on cell viability of A549 cells by colormetric MTT assay Figure 2
Effect of staurosporine on cell viability of A549 cells by colormetric MTT assay. n = 4. Mean ± SD. aP > 0.05, bP < 
0.05, cP < 0.01 vs control. Open circle represents control; solid circle represents 1 nmol/L staurosporine concentration; the 
cross represents 10 nmol/L staurosporine concentration and the open square represents 100 nmol/L staurosporine concentra-
tion
Ultrastructural changes in A549 cells treated with 100 nM/L staurosporine Figure 3
Ultrastructural changes in A549 cells treated with 100 nM/L staurosporine. A: Transmission electron microscopy 
image of an untreated A549 control cell. The nuclear chromatin was homogenized (asterisk), the intracytoplasmic rough endo-
plasmic reticulum was dense (arrows), and there were a large number of ribosomes (arrow heads). A large number of healthy 
microvilli were observed at the cell surface (5,000 ×). B: Transmission electron microscopy image of an A549 cell treated with 
100 nM staurosporine for 24 h. Typical signs of apoptosis were observed. The nuclear chromatin coagulated to a plate-shaped 
structure and gathered in the vicinity of the nuclear membrane (asterisk), the cytoplasmic mitochondria were swollen (arrow 
heads), the endoplasmic reticulum expanded (arrows). The number of microvilli on the cell surface decreased (5,000 ×).BMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
Page 8 of 12
(page number not for citation purposes)
cular endothelium. All of these processes are related to the
adhesion, mobility, and the invasive characteristics of the
tumor cells.
Dumont et al[11] reported that the PKC activator phorbol
12-myristate 13-acetate (PMA) could promote tumor
metastasis in animal models, and PKC inhibitors could
inhibit the tumor metastasis. Haier et al. [12] found that
PMA led to increased adhesion of colon cancer cells to
type I collagen, but PKC inhibitors brought about a
decrease in this adhesion. Furthermore, it was also shown
that PMA could decrease the homogeneity adhesion (the
adhesion between tumor cells) of the colorectal cancer
HT299 cells and increase their heterogeneity adhesion
(adhesion between tumor cells and the extracellular
matrix) to HUVEC3, but PKC inhibitors could antagonize
the above effects [13].
Staurosporine is a potent inhibitor of PKC and most other
kinases (including the tyrosine protein kinases). Here, we
demonstrate that the PKC-α content in the A549 cells
decreased to 22.73% of that in the control group 24 h
after treatment with 100 nM staurosporine (P < 0.01),
while the cytoplasmic PKC-α content did not change sig-
nificantly. This suggests that staurosporine can inhibit
PKC-α activation of the A549 cells and is consistent with
its effect on the cell adhesion, mobility, and invasive capa-
bility of A549 cells.
Effect of staurosporine on membrane localization and level of PKC-α in A549 cells A: representative photo of Western blot Figure 4
Effect of staurosporine on membrane localization and level of PKC-α in A549 cells A: representative photo of 
Western blot. B: Quantification of densitometry. Comparison with the control group * PBMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
Page 9 of 12
(page number not for citation purposes)
The increased heterogeneity adhesion between the tumor
cells and the vascular endothelial cells and the extracellu-
lar matrix is the basis for the mobility and invasion and
metastasis of the tumor cells. Most adhesion receptors are
substrates of PKC. A change in receptor configuration
achieved via PKC-mediated receptor phosphorylation
affects receptor-ligand binding properties, ultimately reg-
ulating the adhesion function. To further explore the
potential mechanisms of staurosporine-mediated inhibi-
tion of cell adhesion in A549 cells, we examined the
changes in adhesion molecules, E-cadherin, LnR, and
integrin β1. E-Cadherin is a calcium-dependent adhesion
molecule mediating the homogeneity adhesion between
cells, which exists widely in various types of epithelial
cells. It can form complexes with intracytoplasmic soluble
protein catenins. Our results show that the E-cadherin
level increased 2.91 times in A549 cells 24 h after treat-
ment with 100 nM staurosporine, suggesting that stau-
rosporine can promote the homogeneity adhesion
between tumor cells.
Laminin (Ln) is the main component of the basement
membrane. The laminin receptor (LnR) on the surface of
the tumor cell can interact with the Ln in the basement
membrane. A large number of in-vitro experiments previ-
ously confirmed that the levels of the LnR on the surface
Effect of staurosporine on the level of integrin β1, E-cadherin, and LnR in A549 cells using Western blot analysis Figure 5
Effect of staurosporine on the level of integrin β1, E-cadherin, and LnR in A549 cells using Western blot analy-
sis. A: representative photo of Western blot. B: Quantification of densitometry indicated increased levels of E-cadherin in 
A549 cells treated with 100 nM stauroporine for 24 h, while integrin β1 and LnR levels were decreased. Intensities are signifi-
cantly different when P < 0.01.BMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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of tumor cells were closely related to heterogeneity adhe-
sion and mobility [14,15]. This study showed that the LnR
protein content in the A549 cells decreased to 57% of that
in the control group 24 hours after treatment with 100 nM
staurosporine.
Our results also show that staurosporine inhibited
integrin  β1 expression. Integrin β1 primarily mediates
adhesion between the cells and the extracellular matrix. Its
ligands are collagen, fibronectin, laminin, and fibrinogen
in the extracellular matrix. It forms "ligand-integrin-trans-
membrane cytoskeleton system" local adhesion devices.
PKC may activate the adhesion of cells through phospho-
rylation of integrin, increasing integrin levels on the cell
surface, reconstruction of the cytoskeleton, or activation
of transcription factors [16].
The integrity of the basement membrane is a key compo-
nent affecting the invasion and metastasis of the tumor.
MMP and uPA are proteases that participate in basement
membrane destruction; they play an important role in the
invasion and metastasis of the tumor. MMP-9 (92 kD
Table 4: Effect of staurosporine on the level of MMP-9 and uPA in A549 cells (  ± s, n = 100)
Group MMP-9 uPA
OD-value P-value OD-value P-value
Control group 0.345 ± 0.039 0.521 ± 0.024
100 nM staurosporine 0.198 ± 0.034 <0.001 0.252 ± 0.038 <0.001
x
Effect of staurosporine on the level of MMP-9 and uPA in A549 cells using fluorescence microscopy (× 200) Figure 6
Effect of staurosporine on the level of MMP-9 and uPA in A549 cells using fluorescence microscopy (× 200). A: 
Control (untreated) A549 cells. The background signal of MMP-9 is relatively high. B: A549 cells treated with 100 nM stau-
rosporine for 24 h. The signal due to MMP-9 decreased. C: Control (untreated) A549 cells. The background signal of uPA is 
relatively high. D: A549 cells treated with 100 nM staurosporine for 24 h. The signal due to uPA decreased.BMC Cancer 2009, 9:174 http://www.biomedcentral.com/1471-2407/9/174
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gelatinase B) is present in many cells, including endothe-
lial cells, fibroblasts, osteoblasts, cartilage cells, and inva-
sive tumor cells. PKC agonist PMA can regulate the
expression of MMPs, TIMPs, uPA receptor, and uPA inhib-
itor PAI-1 [17-19] The immunofluorescence results of this
study showed that a 24-hour treatment with 100 nM stau-
rosporine resulted in 57.39% and 48.37% decreases in the
level of MMP-9 and uPA respectively in A549 cells. This
indicated that staurosporine can decrease the invasive
capability of cancer cells through the inhibition of MMP-
9 and uPA protein levels in lung cancer cells and is con-
sistent with other reports [20-22] We understand the
importance of interpreting these results in the light of the
increased apoptosis observed in staurosporine treated
cells and the resulting loss in cell viability. Additionally,
realizing that staurosporine is a non-specific PKC inhibi-
tor, our future work will include assessing the role of more
specific PKC inhibitors on cell adhesion and mobility in
A549 cells.
Conclusion
In summary, this study illustrates that staurosporine
inhibits cell adhesion, mobility, and invasion of A549
cells. These effects could be mediated through the inhibi-
tion of PKC-α, induction of E-Cad expression, and
decreased integrin β1, LnR, MMP-9 and uPA levels. It is
worth noting that staurosporine is a non-specific PKC
inhibitor with multiple biological effects. Therefore, addi-
tional studies are required to study the effect of stau-
rosporine in other cell lines. Our future goals include
decoding the relationship between the various proteins
tested herein and the staurosporine-mediated decreases in
adhesion, mobility, and invasiveness of A549 lung cancer
cells. Nevertheless, our results represent an important step
forward in understanding the development of lung carci-
noma and designing novel strategies to inhibit metastasis
of the tumor by targeting the adhesion, mobility and inva-
sive properties of these tumor cells.
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